177Lu-Labeled RGD-BBN Heterodimeric Peptide for Targeting Prostate Carcinoma
Lei Jiang,Zheng Miao,Hongguang Liu,Gang Ren,Ande Bao,Cathy S. Cutler,Hongcheng Shi,Zhen Cheng
DOI: https://doi.org/10.1097/mnm.0b013e328362d2b6
2013-01-01
Nuclear Medicine Communications
Abstract:Introduction Radiolabeled Arg-Gly-Asp (RGD) and bombesin (BBN) heterodimers have been investigated for dual targeting of tumor integrin (v3) receptors and gastrin-releasing peptide receptors. The goal of this study was to evaluate the potential use of a Lu-177-labeled RGD-BBN heterodimer for targeted prostate cancer therapy.Materials and methods A 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated RGD-BBN peptide (DO3A-RGD-BBN) was radiolabeled with Lu-177 and purified by high-performance liquid chromatography. The in-vivo biodistribution study of Lu-177-DO3A-RGD-BBN was carried out in mice bearing human prostate cancer PC3 xenografts. The receptor-targeting specificity of the radiolabeled peptide was assayed by injecting the tracer with the unlabeled RGD-BBN peptide. Radiation absorbed doses in adult male patients, based on biodistribution data from mice, were also calculated.Results DO3A-RGD-BBN peptides were successfully labeled with Lu-177, and high radiochemical purity (>95%) could be achieved after high-performance liquid chromatography purification. In human PC3 xenograft-bearing mice, the tumor accumulation of Lu-177-DO3A-RGD-BBN was 5.88 +/- 1.12, 2.77 +/- 0.30, 2.04 +/- 0.19, and 1.18 +/- 0.19%ID/g at 0.5, 2, 24, and 48 h, respectively. With rapid clearance from normal tissues, the radiolabeled probe displayed high tumor-to-blood and tumor-to-muscle ratios. On calculating the radiation absorbed doses for Lu-177-DO3A-RGD-BBN, we found that the prostate tumor and the pancreas were the organs receiving the highest radiation absorbed doses.Conclusion Dual integrin v3 and GPRP-targeted agent Lu-177-DO3A-RGD-BBN shows excellent prostate cancer-targeting ability, and it is worthy of further evaluation for prostate cancer-targeted therapy.